WESTLAKE VILLAGE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced the pricing of an underwritten public offering of 6,666,667 shares of its common stock at a price to the public of $3.00 per share. All of the shares in the offering are to be sold by Genelux. The gross proceeds to Genelux from the offering are expected to be approximately $20.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Genelux. In addition, Genelux has granted the underwriter a 30-day option to purchase up to an additional 1,000,000 shares of its common stock at the price to the public, less underwriting discounts and commissions. The net proceeds from the offering are expected to be used for general...

Kfar Saba, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) — ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, announces that its DefendAir Counter-Unmanned Aerial System (C-UAS) has demonstrated 100% interception success in live field demonstrations against two of the most challenging hostile drone types currently threatening military forces, critical infrastructure, and border security: FPV kamikaze attack drones and DJI FlyCart heavy-lift smuggling drones. Recent field demonstrations, conducted in controlled real-world conditions, showcased DefendAir’s patented net-based, non-explosive interception technology neutralizing both platforms with complete reliability. These results...

Founding CEO Barbara Weber, M.D. to become executive chair of the board of directors Malte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately –BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines today announced the retirement of its Chief Executive Officer, Dr. Barbara Weber, effective today January 8, 2026. Dr. Weber, the company’s founding CEO, will become Executive Chair for 2026 and then serve as non-executive chair starting in 2027. She is succeeded by Dr. Malte Peters, a distinguished leader with extensive clinical development and leadership experience and who has served on the Tango Board of Directors since...

MEXICO CITY, Jan. 08, 2026 (GLOBE NEWSWIRE) — Controladora Vuela Compañía de Aviación, S.A.B. de C.V. (NYSE: VLRS and BMV: VOLAR) (“Volaris” or “the Company”), the ultra-low-cost carrier (ULCC) serving Mexico, the United States, Central and South America, reports its December 2025 preliminary traffic results. In December, Volaris’ ASM capacity increased 9.5%, while RPMs for the month grew 5.1%. Mexican domestic RPMs increased 1.3%, while international RPMs rose 10.7%. Consolidated load factor decreased by 3.5 percentage points year-over-year to 84.1%. During the month, Volaris transported 3.0 million passengers. Enrique Beltranena, Volaris’ President and CEO, said: “In December, demand in our markets reflected a return to historical seasonality and the ongoing recovery in our cross-border VFR market. In the domestic market, we...

Recent marketplace expansions target aerospace, defense and medical sectorsXometry.comXometry marketplace accelerates solutions for complex manufacturing demandsNORTH BETHESDA, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) — Xometry, Inc. (NASDAQ: XMTR), the global AI-powered marketplace connecting buyers and suppliers of custom manufacturing, announced several recent platform enhancements designed to help engineers and procurement professionals keep pace with the rapid evolution of materials and manufacturing processes. With an expanded portfolio of high-performance materials and greater control over manufacturing specifications, Xometry continues to be a partner of choice for resilient, agile supply chains. Expanded High-Performance Materials To support the industry’s shift toward more sophisticated, high-performance applications,...

Community-developed approach combines multi-contact 3C with HiFi sequencing to deliver haplotype-resolved assemblies from minimal input material MENLO PARK, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced CiFi, a new community-developed method that enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even when sample material is limited. By integrating chromatin conformation capture (3C) with PacBio HiFi long-read sequencing, CiFi delivers multi-contact reads and longer fragments that significantly increase the information content of proximity ligation experiments in a single Revio sequencing run. A defining publication just released in Nature Communications by researchers in the Megan Dennis...

First-of-its-kind solution to deliver instant access to top-tier, credible entertainment imagery for personal social media needs of talent and industry professionalsA Media Snippet accompanying this announcement is available by clicking on this link. NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) — Getty Images (NYSE: GETY), a preeminent global visual content creator and marketplace, today announced Access by Getty Images, a new offering developed in partnership with Greenfly, the leader in powering short-form content operations for the world of sports and entertainment, that provides talent, creators and industry professionals with real-time access to premium entertainment imagery for personal social media use for a nominal convenience fee. Access by Getty Images enables talent, along with individual industry professionals, such as...

Company details contemplated transaction structure designed to preserve shareholder value and enable future dividend distributions from core technologies RA’ANANA, Israel, Jan. 08, 2026 (GLOBE NEWSWIRE) — Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (“Inspira,” “Inspira Technologies,” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today outlines its strategic vision and proposed transaction framework for its planned expansion into liquid biopsy diagnostics, outlining a structured approach designed to preserve shareholder value while enabling future dividend distributions the Company’s core respiratory and life-support technologies. This framework underpins a proposed acquisition of an advanced liquid biopsy platform alongside a concurrent...